1-3 of 3
Kantarjian Hagop, MD
Close
Sort by
Journal Articles

Prognostic Factors for Outcome in Patients (pts) with Refractory and Relapsed Acute Lymphocytic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (IO), a CD22 Monoclonal Antibody

Elias Jabbour, MD, Susan O'Brien, MD, Koji Sasaki, Xuelin Huang, PhD, Deborah A. Thomas, MD, Michael E. Rytting, MD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD, Pierce Sherry, RN, Tapan M. Kadia, MD, Kantarjian Hagop, MD
Journal: Blood
Blood (2014) 124 (21): 2288.
https://doi.org/10.1182/blood.V124.21.2288.2288
Published: 2014
Journal Articles

Phase II Study Of The Hyper-CVAD Regimen In Combination With Ofatumumab As Frontline Therapy For Adults With CD-20 Positive Acute Lymphoblastic Leukemia (ALL)

Elias Jabbour, MD, Kantarjian Hagop, MD, Deborah Thomas, MD, Guillermo Garcia-Manero, MD, Daniela Hoehn, MD, PhD, Rebecca Garris, BSc, Stefan H. Faderl, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, Farhad Ravandi, MD, Srdan Verstovsek, MD, PhD, Susan O'Brien, MD
Journal: Blood
Blood (2013) 122 (21): 2664.
https://doi.org/10.1182/blood.V122.21.2664.2664
Published: 2013
Journal Articles

Incidence Of and Risk Factors For Acute Myeloid Leukemia Involvement Of The Central Nervous System

Rozovski Uri, MD, Maro Ohanian, DO, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Stefan H. Faderl, MD, Jorge E. Cortes, MD, Sherry R. Pierce, RN, BS, Kantarjian Hagop, MD, Zeev Estrov, MD
Journal: Blood
Blood (2013) 122 (21): 3883.
https://doi.org/10.1182/blood.V122.21.3883.3883
Published: 2013